Moens A, Alsoud D, Verstockt B, Sabino J, et al. Adalimumab versus ustekinumab as first-line biological in moderate-to-severe Crohn's disease: real-life cohort from a tertiary referral center. Eur J Gastroenterol Hepatol 2022;34:1015-1020.
PMID: 36062494